ClinicalTrials.gg
TerminatedNCT01998828Updated Apr 20, 2020

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

A Phase 2 interventional study of Momelotinib in Polycythemia Vera and Essential Thrombocythemia, sponsored by Sierra Oncology LLC - a GSK company. Terminated at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-20.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies in Polycythemia Vera with a site in United States — 22 open to participants now, 34 under way, 7 of them phase 3. Polycythemia Vera · United States.

Enrollment
79th of 150
39 · median 40
Started
2014
with 6 others
Phase 2
68 of 179
7 open now
Registered
120th of 179
by date

Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 79th largest by enrollment of the 150 interventional ones that give a count, is one of 7 that started in 2014, is one of 68 in phase 2, and was the 120th registered.

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

22 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Polycythemia Vera with a site in United States, or all of them as a file.
02

Study summary

This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.

03

Conditions studied

  • Polycythemia Vera
  • Essential Thrombocythemia

Keywords

  • Polycythemia
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Thrombocytosis
  • Myeloproliferative Disorders
  • Bone Marrow Diseases
  • Hematologic Diseases
  • Blood Coagulation Disorders
  • Blood Platelet Disorders
  • Hemorrhagic Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of either PV or ET as defined by the 2008 World Health Organization (WHO) Diagnostic Criteria
  • Requires treatment for PV or ET, in the opinion of the study investigator
  • Intolerant of, resistant to, or refuses current or available treatment for PV or ET
  • Direct ≤ 2.0 x (ULN)
  • (AST) and alanine transaminase (ALT) ≤ 3 x ULN
  • Calculated (CrCl) of ≥ 45 mL/min
  • > 24 weeks
  • Male subjects and female subjects of who engage in heterosexual intercourse must agree to use protocol specified method(s) of
  • Females who are nursing must agree to discontinue nursing before the first dose of study drug
  • Able to comprehend and willing to sign form

Exclusion criteria

Exclusion Criteria:

  • Prior splenectomy
  • Uncontrolled intercurrent illness, per protocol
  • Known positive status for (HIV)
  • Chronic active or acute viral hepatitis A, B, or C infection, or or C carrier
  • Myeloproliferative neoplasm-directed therapy, other than aspirin, hydroxyurea, anagrelide, and/or phlebotomy, within 21 days prior to the first dose of study drug
  • Anagrelide within 7 days prior to the first dose of study drug
  • Presence of peripheral neuropathy ≥ Grade 2
  • Unwilling or unable to take oral medication
  • Prior use of a JAK1 or JAK2 inhibitor
  • Use of strong inducers within 1 week prior to the first dose of study drug
  • > 450 msec, unless attributed to bundle branch block
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Momelotinib 100 mg PV

    Participants with polycythemia vera will receive 100 mg of momelotinib.

    Drug: Momelotinib

  • Experimental
    Momelotinib 200 mg PV

    Participants with polycythemia vera will receive 200 mg of momelotinib.

    Drug: Momelotinib

  • Experimental
    Momelotinib 100 mg ET

    Participants with essential thrombocythemia will receive 100 mg of momelotinib.

    Drug: Momelotinib

  • Experimental
    Momelotinib 200 mg ET

    Participants with essential thrombocythemia will receive 200 mg of momelotinib.

    Drug: Momelotinib

Interventions

  • Momelotinib tablet administered orally once daily

    Also known as: GS-0387, CYT387

06

What researchers measure

Primary outcomes

  1. Overall response rate

    For the PV Cohort, overall response rate (ORR) is defined as the proportion of participants with all of the following at some point during the treatment period: * Hematocrit \< 45% in the absence of phlebotomy that lasts at least 4 weeks * White blood cell (WBC) count \< 10 x 10\^9/L that lasts at least 4 weeks * Platelet count ≤ 400 x 10\^9/L that lasts at least 4 weeks * Resolution of palpable splenomegaly that lasts at least 4 weeks For the ET Cohort, overall response rate is defined as the proportion of participants with all of the following at some point during the treatment period: * WBC count \< 10 x 10\^9/L that lasts at least 4 weeks * Platelet count ≤ 400 x 10\^9/L that lasts at least 4 weeks * Resolution of palpable splenomegaly that lasts at least 4 weeks

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Confirmed overall response rate

    Confirmed overall response rate is defined as the proportion of participants who meet all the criteria listed for the primary endpoints of PV or ET, sustained for at least 12 weeks.

    Time frame: Up to 24 weeks

  2. Proportion of participants with hematocrit < 45% in the absence of phlebotomy that lasts at least 4 weeks

    Time frame: Up to 24 weeks

  3. Proportion of participants with WBC < 10 x 10^9/L that lasts at least 4 weeks

    Time frame: Up to 24 weeks

  4. Proportion of participants with platelet count ≤ 400 x 10^9/L that lasts at least 4 weeks

    Time frame: Up to 24 weeks

  5. Proportion of participants with resolution of palpable splenomegaly that lasts at least 4 weeks

    Time frame: Up to 24 weeks

  6. Proportion of participants with ≥ 10 point decrease in modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) compared to baseline that lasts at least 12 weeks

    Time frame: Up to 24 weeks

07

Study locations

15 sites
  • Scottsdale, Arizona, United States
  • Whittier, California, United States
  • Tupelo, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Houston, Texas, United States
  • Frankston, Victoria, Australia
  • Parkville, Victoria, Australia
  • Vancouver, British Columbia, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • La Tronche, France
  • Nantes Cedex 1, France
  • Paris, France
  • Dresden, Germany
  • Minden, Germany
08

References and documents

Publications

  • Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017 Sep;60:11-17. doi: 10.1016/j.leukres.2017.05.002. Epub 2017 May 30. PubMed 28622623 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2014 to primary completion in Mar 2015, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2013
First posted
Dec 2, 2013
StartActual
Feb 19, 2014
Primary completionActual
Mar 17, 2015
CompletionActual
May 7, 2015
Results delay requested
Apr 26, 2016
Last update
Apr 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01998828
Responsible party
Sponsor
First posted
Dec 2, 2013
Start date
Feb 19, 2014
Primary completion
Mar 17, 2015
Completion
May 7, 2015
Last update
Apr 20, 2020

Study contacts

Peter Lee, MD, PhD
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Momelotinib

Start the discussion